Vyome Holdings Reports Second-Quarter 2026 Results and Highlights Progress Across Clinical Pipeline
Vyome Holdings, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for immuno-inflammatory and rare diseases, has announced its financial results for the second quarter ended June 30, 2026, while also providing an update on its clinical development programs, business strategy and recent corporate activities.
During the quarter, Vyome continued to prioritize development of its lead investigational program, VT-1953, while also expanding its broader pipeline through an agreement with Impetis Biosciences Limited. The company said it remains focused on disciplined capital allocation as it works to advance its most important clinical opportunities while maintaining financial flexibility.
Krishna Gupta, Chairman of Vyome Holdings, said the company continued to execute its development strategy with a focus on operational discipline and conservative use of capital. During the second quarter, Vyome advanced its VT-1953 program, expanded its pipeline through the Impetis agreement and continued strengthening its intellectual property position.
According to Gupta, the company’s financial position and capital structure provide a foundation for pursuing its development priorities while seeking to generate long-term value for shareholders.
VT-1953 Remains Vyome’s Primary Development Focus
Vyome’s lead development program is VT-1953, a topical gel being investigated for the treatment of malignant fungating wounds (MFW). These wounds can occur in patients with advanced cancers and may be associated with symptoms including unpleasant odor, pain and significant effects on quality of life.
For patients and caregivers, malodor can be particularly difficult to manage and may contribute to social isolation, emotional distress and challenges in daily activities. The company is therefore investigating VT-1953 as a potential treatment designed to address important symptoms associated with malignant fungating wounds.
During 2026, Vyome presented Phase 2 clinical data for VT-1953 at the American Association for Cancer Research (AACR) meeting. The company reported statistically significant improvements in several measures evaluated in the study.
These included a statistically significant reduction in malodor, which represented the primary endpoint of the study. The study also demonstrated a statistically significant improvement in the patient-reported impact of malodor on daily life.
In addition, patients receiving VT-1953 experienced a statistically significant improvement in lesion pain. Vyome reported that no treatment-emergent adverse events were observed in the Phase 2 study.
The company believes the combination of improvements across malodor, quality-of-life impact and lesion pain supports further clinical investigation of VT-1953.
FDA Engagement Advances Clinical Development Plans
Vyome has also continued discussions with the U.S. Food and Drug Administration regarding the future development of VT-1953.
In March 2026, the company submitted a pre-Investigational New Drug (pre-IND) briefing package to the FDA. The submission included Vyome’s proposed strategy for a pivotal clinical study intended to evaluate VT-1953 for the treatment of malodor and other symptoms associated with malignant fungating wounds.
During the second quarter, the company received written feedback from the FDA regarding its proposed clinical development program.
Vyome said it is now incorporating the regulator’s feedback into its development plans and preparing the supporting materials required for the next stage of discussions. The company expects to continue its engagement with the FDA through a Type C meeting.
Such regulatory interactions are intended to help the company further refine the clinical development strategy, including the design and requirements for future pivotal studies.
Venkat Nelabhotla, President and Chief Executive Officer of Vyome, emphasized that VT-1953 remains the company’s leading development priority. He said the Phase 2 results provided encouraging evidence of statistically significant improvements in malodor, the effect of malodor on daily life and lesion pain.
The company now intends to build on those findings as it works with the FDA to determine the appropriate path toward a potential pivotal development program.
Expansion Through Impetis Agreement
While maintaining VT-1953 as its primary focus, Vyome is also pursuing additional opportunities within its broader immuno-inflammatory strategy.
During the quarter, the company entered into an agreement with Impetis Biosciences Limited to in-license two selective Janus kinase (JAK) inhibitor assets. These compounds are designed to provide greater selectivity and potentially address a range of autoimmune and inflammatory diseases.
JAK inhibitors represent an established class of medicines used or investigated across several immune-mediated conditions. By adding selective JAK inhibitor assets to its pipeline, Vyome aims to create additional opportunities in therapeutic areas where significant unmet medical needs remain.
The company said it plans to evaluate and advance these assets in a disciplined manner, with a particular focus on approaches that can reduce the need for dilutive financing.
Vyome stressed that the addition of the Impetis programs does not change its primary focus on VT-1953. Instead, the company views the new assets as complementary opportunities that could expand its future pipeline while maintaining its core strategy in immuno-inflammatory diseases.
Nelabhotla said the company intends to pursue these opportunities selectively while continuing to prioritize VT-1953.
Continued Investment in Intellectual Property
Vyome also reported progress in strengthening its intellectual property portfolio during the second quarter.
The company received a granted Chinese patent covering formulation and therapeutic-use claims associated with its VB-1953 topical gel program for the treatment of inflammatory acne.
The patent adds to Vyome’s intellectual property position around its topical development programs and may provide additional protection for the formulation and potential therapeutic applications of the technology in the Chinese market.
Intellectual property remains an important component of Vyome’s strategy as the company works to develop differentiated therapies in immuno-inflammatory and other areas of unmet medical need.
Stronger Cash Position
Alongside its pipeline progress, Vyome reported an improvement in its cash position during the first six months of 2026.
As of June 30, 2026, the company held approximately $7.9 million in cash and cash equivalents, compared with approximately $5.0 million at December 31, 2025.
Total current assets were approximately $8.2 million as of June 30, while total stockholders’ equity stood at approximately $7.3 million.
The company said its financial position gives it flexibility to continue pursuing its development programs while maintaining a conservative approach to capital allocation.
For the three months ended June 30, 2026, Vyome reported total operating expenses of approximately $874,000. Research and development expenses accounted for approximately $507,000, while selling, general and administrative expenses were approximately $365,000.
Vyome reported a net loss attributable to common shareholders of approximately $720,000, equivalent to approximately $0.10 per basic and diluted share.
The financial results reflect the company’s continued investment in research and development while maintaining relatively controlled operating expenses.
Debt-Free Capital Structure
Vyome highlighted its capital structure as another important component of its corporate strategy.
According to management, the company currently has no debt, no preferred stock and no toxic financing instruments. Management believes this structure provides greater flexibility as it evaluates future development opportunities and determines how best to allocate available capital.
The company intends to balance investment in its clinical programs with financial discipline, particularly as it prepares for potential future clinical development activities involving VT-1953.
This approach could allow Vyome to preserve resources for its most important programs while selectively developing additional pipeline assets.
Focus on Unmet Medical Needs
The company’s strategy remains centered on developing therapies for conditions where patients have significant unmet medical needs.
VT-1953 is currently the most advanced component of that strategy. The program’s Phase 2 results and subsequent FDA engagement represent important steps toward determining whether the therapy can progress into a pivotal clinical development program.
Malignant fungating wounds can represent a substantial burden for patients with advanced cancer. Symptoms such as malodor and lesion pain may affect physical comfort as well as emotional well-being and social interactions. Vyome believes that a therapy capable of improving these symptoms could provide meaningful benefits for patients and caregivers.
The company is now incorporating FDA feedback into its development plans and preparing for additional regulatory discussions through a planned Type C meeting.
At the same time, the Impetis agreement provides Vyome with additional opportunities in autoimmune and inflammatory diseases. The company plans to evaluate the two selective JAK inhibitor assets while maintaining VT-1953 as its central clinical priority.
Outlook for the Remainder of 2026
Looking ahead, Vyome expects its activities to focus on advancing VT-1953 toward the next stage of clinical development, continuing regulatory discussions with the FDA and evaluating its newly licensed JAK inhibitor assets.
The company also plans to continue strengthening its intellectual property portfolio and managing its financial resources carefully.
Management believes that the combination of clinical progress, additional pipeline opportunities and a disciplined capital structure provides Vyome with a solid platform for future development.
The Phase 2 data for VT-1953, particularly the reported improvements in malodor, quality-of-life impact and lesion pain, provide the foundation for the company’s next regulatory and clinical steps. The upcoming Type C meeting with the FDA is expected to be an important opportunity to further discuss the company’s development strategy and determine the appropriate path toward potential pivotal testing.
Meanwhile, the company’s additional selective JAK inhibitor assets could provide longer-term pipeline diversification across autoimmune and inflammatory diseases.
Vyome’s second-quarter update therefore reflects a company balancing near-term clinical priorities with longer-term pipeline expansion. With VT-1953 remaining at the center of its development strategy, the company is continuing to work toward addressing significant unmet needs while maintaining financial and operational discipline.
Complete financial information for the quarter is available in Vyome Holdings’ Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission.
About Vyome Holdings, Inc.:
Vyome is building the world’s premier platform spanning the US-India innovation corridor. Vyome’s immediate focus is on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. By applying groundbreaking science and its unique positioning, Vyome seeks to deliver lasting value to shareholders in a hyper cost-efficient manner while upholding global standards of quality and safety.